transdermal vaccine patches, page-23

Oscar here is my post from Wednesdays Age- the paper had a supplement/Feature on the Melb Biotech Conference this week and POH got this feature write up plus a mention in the intro as an emerging success story- Arcux and Starpharma were in the same sentance as the other future greats of Aust Biotech- impressive stuff. As for Stardom Magazine- yes had forgoten that one- the mag was in Sheraton Hotels in early 2009 if memory serves.

From my earlier post:
3/4 page article with massive pic of Patch patient within todays Age Biotech Feature- this is very good PR for POH today reaching over 200,000 readers:

from the Melb Age 20OCT10:

More than skin deep
By RUSSELL WILLIAMSON
Nobody
enjoys getting an injection but for
millions of diabetes sufferers across the
globe, a regular dose of insulin via a
syringe and needle is part of their reality.
Phosphagenics, a Melbourne-based
biotechnology company focused on the
development of safe, effective and affordable
delivery systems for pharmaceutical and
personal care products, has however,
developed an alternative.
Its patented Tocopheryl Phosphate Mixture
(TPM) technology allows transdermal delivery
through the skin via a patch of molecules
or peptides into the systemic circulation.
TPM is a non-invasive, non-irritant
technology, which enhances the absorption
and solubility of compounds through the skin.
TPM allows for the controlled delivery of
medications using the TPM patch system.
Most drugs on the market are presently
unable to cross the skin barrier and so are taken
orally, leading to potential side effects such as
gastrointestinal problems and use/abuse issues.
However, by offering an alternative means of
delivering the drugs into the circulatory system,
Phosphagenics' TPM has the potential to
alleviate these side-effects in addition to
providing a very controlled and efficient means
of delivery.
Initially, the company has focused its efforts
on developing TPM patches for use in treating
chronic pain and diabetes and has already
completed several Phase I clinical trials with
insulin and the pain products oxycodone and
lidocaine and the anti-inflammatory
compound diclofenac.
These Phase I clinical trialsthat involve
using healthy volunteer subjects to test for
safety and delivery have proven very
positive..
Phosphagen developing a transdermal patch system using its patented TPM technology for the delivery of insulin
Phosphagenics CEO, Dr Esra Ogru says that
although the concept of transdermal delivery
has been around for a while, no other
organisations have been able to progress it as
far as Phosphagenics.
"The beauty of what we're doing here is that
it's not just a single 'drug' it's a whole platform
for drug delivery. We just came out of the trials
thinking that this could well revolutionise the
way real people treat diabetes and pain
management," Dr Esra says.
She says the company is now moving into
Phase II clinical trials but the potential forthe
TPM technology is not just limited to delivering
insulin for diabetics or pain relief.
"Imagine transdermal vaccine delivery. What
happens now with intravenous delivery of
vaccines is that you have to ensure needles are
disposed of properly, that needles are sterile
and often vaccines require refrigeration. There
are lots of complications that a patch will solve,
including the life of the drug," she says.
Phosphagenics has also already made inroads
into the cosmecuetical market with the US
premium cosmetics firm Le Mtier de Beaute's,
launching two TPM cosmetic products under
the Peau de Vierge line late last year.
Earlier this year, a range of skin care products
under the Elixia brand was offered for sale in
Australia using TPM technology.
The products all use TPM to deliver
ingredients such as multi-vitamins, moisturising
oils and retinol into the skin without any
irritation or adverse effects. For Phosphagenics,
the products help create an income stream that
can be used to fund ongoing research into the
application of TPM for conditions such as
diabetes and the chance to change the lives of
millions.
Ends/

KC